Dabuzalgron (previously codenamed R-450; Ro-115-1240) is a novel partial alphaA/IL receptor agonist that is administered in its hydrochloride form to control urethral smooth muscle contraction. The hemodynamic changes in the drug are very small and it is a potential drug for the treatment of stress urinary incontinence.
Dabuzalgron, also known as Ro 115-1240, is an orally active and selective agonist of the α-1A adrenergic receptor used for the treatment of urinary incontinence. Dabuzalgron prevents Doxorubicin-induced cardiotoxicity by protecting mitochondrial function. After 15 minutes of treatment, Dabuzalgron increased ERK phosphorylation in a dose-dependent manner with an EC50 value of 4.8 μM. ERK1/2 activation contributes to the cardioprotective effects of Dabuzalgron. At a concentration of 10 μM for 4 hours, Dabuzalgron protects NRVMs from Doxorubicin-induced cell death. Activation of α1A-AR by Dabuzalgron attenuates the deleterious effects of Doxorubicin on the mitochondrial membrane potential and attenuates the activation of factors important for the apoptotic response resulting from mitochondrial damage[1].
Dabuzalgron 实验方案
计算器
存储液制备
1mg
5mg
10mg
1 mM
5 mM
10 mM
3.15mL
0.63mL
0.31mL
15.73mL
3.15mL
1.57mL
31.47mL
6.29mL
3.15mL
Dabuzalgron 技术信息
CAS号
219311-44-1
分子式
C12H16ClN3O3S
分子量
317.79
SMILES Code
CS(=O)(NC1=C(Cl)C=CC(OCC2=NCCN2)=C1C)=O
MDL No.
MFCD13195546
别名
Ro 115-1240
运输
蓝冰
存储条件
In solvent-20°C:3-6个月-80°C:12个月
Pure formSealed in dry, store in freezer, under -20°C
搜索
